Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial.
Woll P, Gaunt P, Danson S, Steele N, Ahmed S, Mulatero C, Shah R, Bhosle J, Hodgkinson E, Watkins B, Billingham L. Woll P, et al. Among authors: bhosle j. Lung Cancer. 2022 Sep;171:26-33. doi: 10.1016/j.lungcan.2022.07.007. Epub 2022 Jul 15. Lung Cancer. 2022. PMID: 35872530 Free article. Clinical Trial.
Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.
Cui W, Milner-Watts C, O'Sullivan H, Lyons H, Minchom A, Bhosle J, Davidson M, Yousaf N, Scott S, Faull I, Kushnir M, Nagy R, O'Brien M, Popat S. Cui W, et al. Among authors: bhosle j. Eur J Cancer. 2022 Aug;171:44-54. doi: 10.1016/j.ejca.2022.05.012. Epub 2022 Jun 12. Eur J Cancer. 2022. PMID: 35704974 Free article.
Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer.
Jabbour SK, Cho BC, Bria E, Kato T, Bhosle J, Gainor JF, Reguart N, Wang L, Morgensztern D, Shentu Y, Kim SJ, Souza F, Reck M. Jabbour SK, et al. Among authors: bhosle j. Clin Lung Cancer. 2022 Sep;23(6):e342-e346. doi: 10.1016/j.cllc.2022.04.003. Epub 2022 Apr 29. Clin Lung Cancer. 2022. PMID: 35618629 Free PMC article. Clinical Trial.
Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19.
Várnai C, Palles C, Arnold R, Curley HM, Purshouse K, Cheng VWT, Booth S, Campton NA, Collins GP, Hughes DJ, Kulasekararaj AG, Lee AJX, Olsson-Brown AC, Sharma-Oates A, Van Hemelrijck M, Lee LYW, Kerr R, Middleton G, Cazier JB; UKCCMP Team. Várnai C, et al. JAMA Netw Open. 2022 Feb 1;5(2):e220130. doi: 10.1001/jamanetworkopen.2022.0130. JAMA Netw Open. 2022. PMID: 35188551 Free PMC article.
Immune Checkpoint Inhibitor and Radiotherapy-Related Pneumonitis: An Informatics Approach to Determine Real-World Incidence, Severity, Management, and Resource Implications.
Hindocha S, Campbell D, Ahmed M, Giorgakoudi K, Sharma B, Yousaf N, Molyneaux P, Hunter B, Kalsi H, Cui W, Davidson M, Bhosle J, Minchom A, Locke I, McDonald F, O'Brien M, Popat S, Lee RW. Hindocha S, et al. Among authors: bhosle j. Front Med (Lausanne). 2021 Nov 1;8:764563. doi: 10.3389/fmed.2021.764563. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34790682 Free PMC article.
HER3 expression and MEK activation in non-small-cell lung carcinoma.
Manickavasagar T, Yuan W, Carreira S, Gurel B, Miranda S, Ferreira A, Crespo M, Riisnaes R, Baker C, O'Brien M, Bhosle J, Popat S, Banerji U, Lopez J, de Bono J, Minchom A. Manickavasagar T, et al. Among authors: bhosle j. Lung Cancer Manag. 2021 Apr 9;10(2):LMT48. doi: 10.2217/lmt-2020-0031. Lung Cancer Manag. 2021. PMID: 34084213 Free PMC article.
41 results